Research Article

CYP1B1 G199T Polymorphism Affects Prognosis of NSCLC Patients with the Potential to Be an Indicator and Target for Precise Drug Intervention

Table 4

Cox’s proportional hazard regression model for multivariate analysis.

VariablesDisease-free survivalOverall survival
Exp (B)/HR95% CIExp (B)/HR95% CI
LowerUpperLowerUpper

Gender (male)0.0881.6790.9263.0450.2651.4000.7752.529
Age (≥66)0.1801.4120.8522.3390.1021.5390.9182.580
Smoking (never)0.0880.6230.3621.0740.0820.6080.3471.064
Pathological type
 AD0.014 1.0000.001 1.000
 SQ0.1370.6240.3351.1620.2300.6740.3541.284
 LA0.050 2.0180.9994.0780.005 2.8341.3715.859
 Others0.6420.7750.2642.2730.8711.0960.3633.306
Differentiation
 Poor0.1391.0000.0281.000
 Moderate0.2560.7530.4621.2280.1550.7000.4281.144
 Well0.0550.4120.1671.0180.009 0.2550.0910.712
T stage
 T10.002 1.0000.001 1.000
 T20.000 4.0511.8588.8350.000 4.3201.9789.435
 T30.040 2.4221.0405.6400.007 3.1711.3797.290
 T40.003 5.5241.78317.1090.001 7.8592.42525.467
N stage
 N00.1611.0000.031 1.000
 N10.5720.7630.2991.9480.9321.0430.3982.734
 N20.1701.6590.8053.4180.014 2.6131.2125.630
 N30.3132.2360.46910.6670.2152.6810.56512.719
M stage (M1)0.001 5.4992.07914.5430.002 4.7081.74612.689
Clinical
 I0.049 1.0000.1151.000
 II0.005 6.2741.72522.8160.018 4.8781.31618.076
 IIIa0.0892.3120.8816.0640.3021.7010.6214.658
 IIIb0.2192.4130.5939.8240.5221.5950.3836.647
G199T (mutant)0.4911.1760.7421.8630.4781.1850.7411.896
C432G (mutant)0.5361.2000.6742.1380.6651.1370.6372.30

or linearly dependent covariates clinical stage V = M stage 1.